Dr Reddy's confirms voluntary license for Gilead's HIV prevention drug

Business Updates View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹1175.00

prior close

₹1182.60

announcement price

After-mkt

timing

Nifty 100market+0.5%+0.4% vs market

Pharmaceuticals peers, median of 172sector+0.6%+0.3% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.8

15m

+1.1

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9+0.5+0.4+0.6+0.3

Next day

+2.3+0.7+1.5+1.1+1.2

+2.7+0.4+2.3+1.1+1.7

+3.4+1.0+2.4+2.0+1.3

+2.2-0.7+2.8+0.8+1.4

+2.2-0.3+2.5+0.5+1.7

+6.5-2.4+8.9+0.1+6.4

15d

+4.6-3.9+8.5-4.3+9.0

+5.7-2.0+7.7-6.1+11.8

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Reddy's confirmed to BSE that it has entered a voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention. The clarification follows a media report and refers to the company's September 17 press release about expanding its collaboration with Gilead. The company stated there is no further undisclosed material information and the matter does not require additional disclosure under Regulation 30.

Likely market impact

Strengthens Dr Reddy's HIV pipeline and partnership with major originator Gilead. Positive for long-term portfolio, drug still investigational.